54 results
8-K
EX-10.1
PRPO
Precipio Inc
6 Mar 14
Transgenomic Announces $7 Million Convertible Preferred Stock Financing
12:00am
material respects (other than any representation or warranty that is qualified by materiality or Material Adverse Effect, in which case such representation … true and correct in all material respects (other than any representation or warranty that is qualified by materiality or Material Adverse Effect
8-K
EX-10.1
PRPO
Precipio Inc
22 Oct 14
Transgenomic Announces $2.375 Million Private Placement Financing
12:00am
to be made under the Loan Documents are true and correct in all material respects (other than any representation or warranty that is qualified by materiality … that is qualified by materiality or Material Adverse Effect, in which case such representation or warranty was true and correct in all respects
8-K
PRPO
Precipio Inc
22 Jul 20
Precipio Announces Q2-2020 Unaudited Pathology Services Revenue Increased Approximately 50% over Q1’20
4:00pm
general incorporation language in such filing. The furnishing of this information hereby shall not be deemed an admission as to the materiality of any
8-K
PRPO
Precipio Inc
11 Mar 19
Precipio CEO Issues Shareholder Update Letter
4:50pm
as to the materiality of any such information.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
99.1 Precipio Inc’s letter to shareholders dated
8-K
isxgvr ns
26 Mar 24
Precipio Announces Year end 2023 Shareholder Update Call
4:34pm
8-K
nw9 cr3r75j71
3 Nov 22
Precipio Announces Third Quarter Shareholder Update Call
7:21pm
8-K
31z7jngr
3 Oct 19
Precipio announces shareholder update call on commercial progress
12:00am
8-K
5jwyuh95h2zxywe n2
20 Jun 19
Precipio CEO Provides Update Letter To Shareholders
5:03pm
8-K
b1xqle
2 Nov 21
Precipio Announces Q3-2021 Shareholder Update Call
12:00am
8-K
cna32
13 May 20
Precipio Announces Q1-2020 Corporate Update Call For Shareholders
12:00am
8-K
n9vvni8 6t
26 Sep 19
Clinical Validations for IV-Cell™ and HemeScreen™ Completed
4:43pm
8-K
u8tta
16 Mar 20
Precipio Completes the Transaction with Poplar Healthcare’s Oncometrix Hematopathology Division
4:17pm
8-K
kbvcaryaiek n8jf2c
13 Aug 21
Precipio Announces Q2-2021 Shareholder Update Call
12:00am
8-K
ct2rcueqzkdbr1t3
14 Aug 23
Precipio Announces Q2-2023 Shareholder Update Call
4:00pm
8-K
q1kjjm8xb9nys0txes
28 Jul 21
Precipio Announces Preliminary Unaudited Q2-2021 Revenues of $2.3M
4:41pm
8-K
3lg sb18qt8
23 Aug 21
Precipio Reschedules Q2-2021 Shareholder Update Call
12:00am
8-K
1lssw62lp8mkl leia
17 May 21
Precipio Announces Q1-2021 and year-end Shareholder Update Call
11:22am
8-K
tzgeh0b3 bl
4 Sep 20
Precipio Announces a Shareholder Call to Discuss its COVID-19 Progress and Future Plans
4:00pm
8-K
7lszj 0m16h3hfh3
5 Nov 19
Precipio Announces Q3-2019 Corporate Update Call for Shareholders
4:00pm